In Spain, 3710 patients treated with statin therapy for at least 3 months were included. We compared data relating to demographic parameters and cardiovascular risk profile.

Results: Complete lipid profiles of 3617 patients were recorded. Regarding the high cardiovascular risk patients with complete lipid profiles (n = 2273), 78.9% had a disorder JNJ-26481585 in vivo in at least one of the three main lipid parameters: low-density lipoprotein cholesterol (LDLc), high-density lipoprotein cholesterol

(HDLc) and/or triglycerides. LDLc was not within target levels in 61.4% of these high risk patients; HDLc was abnormal in 25.3%, and triglycerides were elevated in 37.8%. Overall, LDLc was outside the target range in 63.1%,

and 20.7% (n = 668) of those treated with statins were normal for all parameters.

Conclusions: Most patients in this study who received statin therapy, particularly those at high cardiovascular risk, were not at the normal lipid parameter levels according to cardiovascular guidelines. Although it is necessary to wait for the final results of current studies on the use of combined lipid-modifying treatments, the management of lipid levels in Spain still has potential for improvement. (C) 2010 Sociedad Espanola de Cardiologia. Published by Elsevier Espana, S. L. All rights reserved.”
“Taxol-loaded nanoparticles were prepared by solvent-evaporation technique with methoxy-added methoxy poly(ethylene glycol)-b-poly(epsilon-caprolactone) (MPEG-b-PCL) (PEG wt % = 18.5%) as drug carrier and MPEG-b-PCL (PEG wt % = PD98059 manufacturer 86.8%) as the additive in the outer aqueous phase. The MPEG-b-PCL copolymers were synthesized via ring-opening polymerization of epsilon-caprolactone using Novozym 435 as biocatalyst. As a newly used additive in the outer aqueous phase, only 0.1% (w/v) MPEG-b-PCL with relatively high-PEG content was needed. The effects of feed ratio of taxol to copolymer (w/w, 5-20%) on the characters of nanoparticles and in vitro drug release were investigated.

The fabricated nanoparticles reached the Selleckchem MK-8776 highest encapsulation efficiency of 52.5% +/- 3.9% when the feed ratio was 10%. The nano-particles presented a core-shell structure in aqueous solution, and their hydrodynamic diameter ranged from 75 to 105 nm. Transmission electron microscopy and atomic force microscope investigations exhibited that the nanoparticles had fine spherical shape and narrow particle size distribution. The size of nanoparticles did not change distinctly after incubation in pH 7.4 phosphate-buffered solution (PBS) and pH 7.4 PBS with 10% fetal bovine serum at 37 degrees C for 24 h. The nanoparticles with drug loading around 5% could achieve a sustained drug release for 7 days. (C) 2011 Wiley Periodicals, Inc.